Pfizer completes $7.0 billion acquisition of obesity drug developer Metsera
Pfizer said on November 13, 2025 that it completed its acquisition of Metsera, Inc. under a merger agreement dated September 21, 2025, as amended November 7, 2025. Metsera holders receive $65.60 per share in cash at closing, an enterprise value of approximately $7.0 billion, plus contingent value rights worth up to $20.65 per share tied to three milestones. The deal adds Metsera's GLP-1-based weight-loss drug candidates to Pfizer's pipeline, but the milestone payments depend on future clinical and regulatory events.
Key points
- Closing cash consideration of $65.60 per Metsera share, an enterprise value of approximately $7.0 billion
- Contingent value rights of up to $20.65 per share in cash across three milestones
- Milestones: $4.60 on Phase 3 trial start for MET-097i+MET-233i; $6.40 on FDA approval of MET-097i monotherapy; $9.65 on FDA approval of the combination
- Deal completed November 13, 2025 via Mayfair Merger Sub, Inc., a wholly owned subsidiary
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:16 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 13, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.